NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2015-03-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT00006509

Locations: 🇺🇸
Aaron Diamond AIDS Res Ctr, New York, New York, United States

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000846

Locations: 🇺🇸
Univ of Rochester Med Ctr, Rochester, New York, United States
🇺🇸
Univ of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Univ of Washington / Pacific Med Ctr, Seattle, Washington, United States

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

Phase 3

Terminated

Conditions: Kidney Transplantation

Interventions: Drug: hOKT3
Drug: Oral Cyclosporine
Drug: IV Cyclosporine

First Posted Date: 2001-08-31

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 292

Registration Number: NCT00000936

Locations: 🇺🇸
Ilene Blechman-Krom, Rockville, Maryland, United States

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

Phase 3

Withdrawn

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2015-05-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00011128

Locations: 🇺🇸
Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States

and more 27 locations

Heterosexual HIV Transmission Study (HATS)

Completed

Conditions: HIV Infections
Healthy

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000783

Locations: 🇺🇸
UMDNJ - New Jersey Med School, Newark, New Jersey, United States

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000792

Locations: 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸
NY Univ. HIV/AIDS CRS, New York, New York, United States

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000904

Locations: 🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States
🇺🇸
UAB AVEG, Birmingham, Alabama, United States
🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States

and more 3 locations

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity

Interventions: Biological: Placebo version of rgp120/HIV-1MN
Biological: rgp120/HIV-1MN
Biological: rgp120/HIV-1 SF-2
Biological: Placebo version of rgp120/HIV-1SF2

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 156

Registration Number: NCT00000774

Locations: 🇺🇸
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States

and more 34 locations

Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT00000670

Locations: 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States

A Study of Azidothymidine in HIV-Infected Children

Phase 2

Completed

Conditions: Encephalopathies
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT00000982

Locations: 🇺🇸
Walter Reed / USUHS / Pediatrics, Bethesda, Maryland, United States
🇺🇸
Children's Hosp at Albany Med Ctr, Albany, New York, United States
🇺🇸
Univ of Florida Med Ctr, Jacksonville, Florida, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy